{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T18:15:36Z","timestamp":1783361736758,"version":"3.54.6"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["INDEEP"],"award-info":[{"award-number":["INDEEP"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["MSNZ"],"award-info":[{"award-number":["MSNZ"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background\/aims<\/jats:title>\n                    <jats:p>Initially unresectable colorectal liver metastases may become resectable after chemotherapy. The acquisition of somatic mutations has been demonstrated to indicate evolving tumor subclones resistant to therapy and hinder R0 resection. However, the added value of mutational profiling in a real-world setting remains to be elucidated. The objective of the present study was to identify recurrent molecular profiles in colorectal cancer liver metastases that had been pre-treated with anti-EGFR monoclonal antibodies plus chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, single-centre analysis of colorectal cancer liver metastases samples from 30 patients (9 pre-therapy\/21 post-therapy) who received chemotherapy and anti-EGFR agents between January 2008 and February 2014 was conducted. Targeted next-generation resequencing (NGS) was performed. Subsequently, the results were compared to publicly available genomic datasets of primary colorectal cancer and colorectal cancer liver metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>145 mutations were identified (mean, 5.2\u2009\u00b1\u20091.3 mutations per sample; range 0\u201328, median 2, IQR 3.75). Neither mutation count nor RAS status did correlate with the achievement of resectability. NGS confirmed prior identified KRAS mutations in 4\/29 patients (14.8%) and revealed further somatic RAS alterations in 5 cases. In addition to the classical colorectal cancer driver mutations, tumors exhibited recurrent mutations in genes implicated in anti-EGFR resistance such as HNF1A (34.4%, 10\/29), FGFR2 (31%, 9\/29), VHL (27.5%, 8\/29) and PDGFR (27.5%, 8\/29), ERBB2 (24.1%, 7\/29), ABL1 (24.1%, 7\/29), SMO (24.1%, 7\/29), GNA11 (20.6%, 6\/29), RET (20.6%, 6\/29), STK11 (20.6%, 6\/29), HRAS (20.6%, 6\/29) and NRAS (17.2%, 5\/29).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In the current study, we describe a higher frequency of potential anti-EGFR treatment resistance mutations in patients who respond well to the combination of chemotherapy and anti-EGFR monoclonal antibody treatment. Nevertheless, subclonal mutations associated with resistance to anti-EGFR therapy did not affect the secondary resectability of colorectal liver metastases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0351243","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:29:40Z","timestamp":1783358980000},"page":"e0351243","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Higher frequency of subclonal anti-EGFR resistance mutations in post-treatment samples from patients with colorectal cancer liver metastases following anti-EGFR-based conversion chemotherapy"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6991-9910","authenticated-orcid":true,"given":"Christoph","family":"Steup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Mondorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Pession","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3267-8145","authenticated-orcid":true,"given":"Wolf Otto","family":"Bechstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9305-3691","authenticated-orcid":true,"given":"Florian A.","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Trojan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"1","key":"pone.0351243.ref001","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"RL Siegel","year":"2024","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"pone.0351243.ref002","author":"U European","year":"2024"},{"issue":"1","key":"pone.0351243.ref003","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41698-023-00353-4","article-title":"Survival improvement for patients with metastatic colorectal cancer over twenty years","volume":"7","author":"FA Zeineddine","year":"2023","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"pone.0351243.ref004","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"A Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"pone.0351243.ref005","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of Metastatic Colorectal Cancer: ASCO Guideline","volume":"41","author":"VK Morris","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"pone.0351243.ref006","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdx738","article-title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS","volume":"29","author":"T Yoshino","year":"2018","journal-title":"Ann Oncol"},{"issue":"13","key":"pone.0351243.ref007","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"C Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"issue":"11","key":"pone.0351243.ref008","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"J-Y Douillard","year":"2013","journal-title":"N Engl J Med"},{"issue":"9863","key":"pone.0351243.ref009","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"A Grothey","year":"2013","journal-title":"Lancet"},{"issue":"20","key":"pone.0351243.ref010","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"RJ Mayer","year":"2015","journal-title":"New England J Med"},{"issue":"1","key":"pone.0351243.ref011","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s42003-024-05965-5","article-title":"EGFR signaling and pharmacology in oncology revealed with innovative BRET-based biosensors","volume":"7","author":"F Gross","year":"2024","journal-title":"Commun Biol"},{"issue":"10","key":"pone.0351243.ref012","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1158\/2159-8290.CD-12-0103","article-title":"Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors","volume":"2","author":"D Ercan","year":"2012","journal-title":"Cancer Discov"},{"issue":"1","key":"pone.0351243.ref013","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41571-025-01085-z","article-title":"Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches","volume":"23","author":"J Zhao","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"issue":"7404","key":"pone.0351243.ref014","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"S Misale","year":"2012","journal-title":"Nature"},{"issue":"2","key":"pone.0351243.ref015","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/2159-8290.CD-17-1009","article-title":"Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer","volume":"8","author":"JH Strickler","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"pone.0351243.ref016","doi-asserted-by":"crossref","first-page":"7014","DOI":"10.1038\/s41467-021-27276-7","article-title":"Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids","volume":"12","author":"K Gong","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"pone.0351243.ref017","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/s43018-024-00781-6","article-title":"A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance","volume":"5","author":"CE Whitehead","year":"2024","journal-title":"Nat Cancer"},{"issue":"12","key":"pone.0351243.ref018","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1136\/gutjnl-2025-335412","article-title":"Current and emerging concepts for systemic treatment of metastatic colorectal cancer","volume":"74","author":"C Steup","year":"2025","journal-title":"Gut"},{"key":"pone.0351243.ref019","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","article-title":"The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials","volume":"70","author":"JW Holch","year":"2017","journal-title":"Eur J Cancer"},{"issue":"15","key":"pone.0351243.ref020","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial","volume":"329","author":"J Watanabe","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"pone.0351243.ref021","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/s41416-025-03164-5","article-title":"Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials","volume":"133","author":"A Ballhausen","year":"2025","journal-title":"Br J Cancer"},{"issue":"7407","key":"pone.0351243.ref022","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"issue":"4","key":"pone.0351243.ref023","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.celrep.2016.03.075","article-title":"Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma","volume":"15","author":"M Giannakis","year":"2016","journal-title":"Cell Rep"},{"issue":"8","key":"pone.0351243.ref024","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jamaoncol.2016.0173","article-title":"Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer","volume":"2","author":"AG Sacher","year":"2016","journal-title":"JAMA Oncol"},{"issue":"4","key":"pone.0351243.ref025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000490888","article-title":"Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates","volume":"98","author":"C Koch","year":"2018","journal-title":"Digestion"},{"issue":"7","key":"pone.0351243.ref026","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/annonc\/mdn058","article-title":"Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK","volume":"19","author":"M Borner","year":"2008","journal-title":"Ann Oncol"},{"issue":"33","key":"pone.0351243.ref027","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1200\/JCO.2007.13.2183","article-title":"Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer","volume":"25","author":"J Tabernero","year":"2007","journal-title":"J Clin Oncol"},{"issue":"7","key":"pone.0351243.ref028","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.2009.24.6116","article-title":"Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer","volume":"28","author":"A Bardelli","year":"2010","journal-title":"J Clin Oncol"},{"issue":"17","key":"pone.0351243.ref029","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"CS Karapetis","year":"2008","journal-title":"N Engl J Med"},{"issue":"7572","key":"pone.0351243.ref030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nature14969","article-title":"The genomic landscape of response to EGFR blockade in colorectal cancer","volume":"526","author":"A Bertotti","year":"2015","journal-title":"Nature"},{"issue":"8","key":"pone.0351243.ref031","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"W De Roock","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"pone.0351243.ref032","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies","volume":"40","author":"J Zhou","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"pone.0351243.ref033","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.22.00364","article-title":"Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer","volume":"41","author":"JT Topham","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"pone.0351243.ref034","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/bjc.2016.74","article-title":"Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies","volume":"114","author":"N Takahashi","year":"2016","journal-title":"Br J Cancer"},{"key":"pone.0351243.ref035","doi-asserted-by":"crossref","unstructured":"Ojala VK, Ahonen S, Tuohisto-Kokko A, Esparta O, Suominen P, Jokilammi A. Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies. 2024.","DOI":"10.1101\/2024.12.19.626686"},{"issue":"15","key":"pone.0351243.ref036","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.18632\/oncotarget.1866","article-title":"FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor","volume":"5","author":"K Azuma","year":"2014","journal-title":"Oncotarget"},{"issue":"7","key":"pone.0351243.ref037","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1541-7786.MCR-12-0652","article-title":"Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC","volume":"11","author":"H Terai","year":"2013","journal-title":"Mol Cancer Res"},{"issue":"11","key":"pone.0351243.ref038","article-title":"Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression","volume":"5","author":"KE Ware","year":"2010","journal-title":"PLoS One"},{"issue":"2","key":"pone.0351243.ref039","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nm.2609","article-title":"Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer","volume":"18","author":"C Montagut","year":"2012","journal-title":"Nat Med"},{"issue":"23","key":"pone.0351243.ref040","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1158\/1078-0432.CCR-19-0823","article-title":"Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies","volume":"25","author":"CM Parseghian","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"16","key":"pone.0351243.ref041","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1200\/JCO.2008.20.2796","article-title":"PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer","volume":"27","author":"F Loupakis","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0351243.ref042","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2217\/lmt-2016-0005","article-title":"Targeting EGFR and ALK in NSCLC: current evidence and future perspective","volume":"5","author":"C Bennati","year":"2016","journal-title":"Lung Cancer Manag"},{"issue":"3","key":"pone.0351243.ref043","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-023-02791-w","article-title":"Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer","volume":"30","author":"K Shitara","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"pone.0351243.ref044","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0046-8177(96)90368-8","article-title":"von Hippel-Lindau disease gene deletion detected in microdissected sporadic human colon carcinoma specimens","volume":"27","author":"Z Zhuang","year":"1996","journal-title":"Hum Pathol"},{"issue":"3","key":"pone.0351243.ref045","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.22.01423","article-title":"Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS\/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy","volume":"41","author":"CM Parseghian","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"pone.0351243.ref046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.05.013","article-title":"Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer","volume":"36","author":"A Woolston","year":"2019","journal-title":"Cancer Cell"},{"issue":"6","key":"pone.0351243.ref047","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3390\/cancers12061393","article-title":"Anti-EGFR Therapy Induces EGF Secretion by Cancer-Associated Fibroblasts to Confer Colorectal Cancer Chemoresistance","volume":"12","author":"CM Garvey","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"269","key":"pone.0351243.ref048","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"J Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"23","key":"pone.0351243.ref049","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal","volume":"83","author":"I de Bruijn","year":"2023","journal-title":"Cancer Res"},{"issue":"5","key":"pone.0351243.ref050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"E Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"12","key":"pone.0351243.ref051","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/jnci\/djab124","article-title":"A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers","volume":"113","author":"A Cercek","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"pone.0351243.ref052","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41588-021-00791-5","article-title":"The NCI Genomic Data Commons","volume":"53","author":"AP Heath","year":"2021","journal-title":"Nature Genetics"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:29:54Z","timestamp":1783358994000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351243"}},"subtitle":[],"editor":[{"given":"Jad","family":"El Masri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":52,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0351243","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}